MED Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Medifast Inc (MED) is not a good buy for a beginner investor with a long-term strategy at this time. The company's financial performance is deteriorating significantly, with sharp declines in revenue, net income, and EPS. Additionally, the lack of positive trading signals, weak technical indicators, and no recent positive news or catalysts make this stock unsuitable for investment currently.
The MACD is slightly positive at 0.0248, indicating mild bullish momentum, but the RSI at 62.361 is neutral. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its resistance level (R1: 10.805). Overall, the technical indicators do not suggest a strong buying opportunity.
NULL identified. No recent news or events suggest a positive catalyst for the stock.
Analysts have also lowered the price target from $15 to $12, citing concerns about growth in the coach count.
In Q4 2025, Medifast reported a revenue drop to $75.1M (-36.90% YoY), a net income loss of -$18.1M (-2362.05% YoY), and an EPS decline to -1.65 (-2457.14% YoY). Gross margin also dropped to 69.43%, down -6.34% YoY.
Stephens recently lowered the price target from $15 to $12 and maintained an Equal Weight rating, citing concerns about growth in the coach count despite operational discipline and restructuring efforts.
